Organization (Industry)
DEXCOM, INC.
ClinicalTrials.gov lists DEXCOM, INC. as lead sponsor of 35 trials. It has 2 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 8 in 2026 and about 13 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers DEXCOM, INC.: 35 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (31)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 143 |
| Diabetes Mellitus, Type 1 | 69 |
| Diabetes Mellitus, Type 2 | 28 |
| Hyperglycemia | 14 |
| Diabetes, Gestational | 10 |
Showing 5 of 31 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 17 |
| 2024 | 10 |
| 2023 | 13 |
| 2022 | 17 |
| 2021 | 22 |
| 2020 | 19 |
| 2019 | 13 |
| 2018 | 11 |
| 2017 | 6 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: none of the 35 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Basal Insulin | Diabetes Mellitus | Phase 1 | 1 |
| Basal Insulin | Diabetes Mellitus, Type 2 | Phase 1 | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=5) | 1 of 4 on time (n=4) |
Journals published in (143)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes care | 71 |
| Diabetes technology & therapeutics | 46 |
| The New England journal of medicine | 19 |
| JAMA | 16 |
| Journal of diabetes science and technology | 13 |
Showing 5 of 143 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 975 | 297 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 4,662,000,000 | 836,300,000 | 599,100,000 |
| 2024 | 4,033,000,000 | 576,200,000 | 552,400,000 |
| 2023 | 3,622,300,000 | 541,500,000 | 505,800,000 |
| 2022 | 2,909,800,000 | 341,200,000 | 484,200,000 |
| 2021 | 2,448,500,000 | 216,900,000 | 517,100,000 |
| 2020 | 1,926,700,000 | 549,700,000 | 359,900,000 |
| 2019 | 1,476,000,000 | 101,100,000 | 273,500,000 |
| 2018 | 1,031,600,000 | -127,100,000 | 199,700,000 |
| 2017 | 718,500,000 | -50,200,000 | 185,400,000 |
| 2016 | 573,300,000 | -65,600,000 | 156,100,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (23)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-14 | Other financing | not disclosed | Sec extracted |
| 2026-02-27 | Other financing | not disclosed | Sec extracted |
| 2025-05-01 | Other financing | not disclosed | Sec extracted |
| 2025-02-18 | Follow-on offering | not disclosed | Edgar offerings |
| 2024-07-25 | Other financing | not disclosed | Sec extracted |
Showing 5 of 23 events.
FDA warning letters (1)
| Issue date | Letter |
|---|---|
| 2025-03-04 | dexcom-inc-700835-03042025 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 12 |
FDA recalls (29)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 US Retail Sensor/Transmitter 1-pack Model/Catalog Number: STP-AT-012 Software Version: N/A Product Description: Dexcom G7 US Retail Sensor/Transmitter 1-pack Component: Dexcom G7 Continuous Glucose Monitoring System | Class II | 2026-05-27 |
| Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: Versions 2.9.0 through 2.11.2 Product Description: Dexcom G7 CGM iOS App Component: Dexcom G7 Continuous Glucose Monitoring System, Dexcom G7 15 Day Continuous Glucose Monitoring System | Class II | 2026-04-14 |
| Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: Versions 2.9.0 through 2.11.2 Product Description: Dexcom G7 CGM watchOS App - The watchOS app is installed along with the iOS phone app and the versions used are the same for each user. The watchOS app cannot be installed independently from the iOS phone app. Component: Dexcom G7 Continuous Glucose Monitoring System, Dexcom G7 15 Day Continuous Glucose Monitoring System | Class II | 2026-04-14 |
| Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.5.0 and 1.6.0 Product Description: Dexcom ONE+ iOS CGM App Component: Dexcom ONE+ Continuous Glucose Monitoring System | Class II | 2026-04-14 |
| Brand Name: Dexcom G6 Continuous Glucose Monitoring System Product Name: Dexcom G6 and G6 Pro Android US CGM App Model/Catalog Number: SW11678 Software Version: version 1.15.0 Product Description: Dexcom G6 and G6 Pro Android US CGM App SW11678 version 1.15.0 Component: Dexcom G6 Continuous Glucose Monitoring System | Class I | 2025-08-28 |
Showing 5 of 29 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 6 | 2025-06-05 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| DEXCOM, INC. | SAN DIEGO, US | FDA | |
| Dexcom, Inc. | Mesa, US | FDA | |
| Dexcom, Inc. | Mesa, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 48.6% | not disclosed |
Organization relationships (91)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Virginia | Co sponsors trial with | 25 |
| Tandem Diabetes Care Inc | Co sponsors trial with | 23 |
| Government of the United States of America | Co sponsors trial with | 15 |
| Jaeb Center for Health Research | Co sponsors trial with | 6 |
| University of California System | Co sponsors trial with | 5 |
Showing 5 of 91 relationships.
Latest dated events (1,216)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-27 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-05-14 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,216 events.
Biomarker capability evidence (190)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGA | Trial collaborator | Named in trial inclusion criteria |
| AICDA | Trial collaborator | Named in trial inclusion criteria |
| AICDA | Trial collaborator | Named in trial inclusion criteria |
| AICDA | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 190 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.